Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
Non-COVID prescription medicines didn’t stop launching during the pandemic — approvals by both the FDA and the EMA were, in fact historically high in both 2020 and 2021. Telemedicine rose dramatically in many countries, providing a route to managing ongoing care which was a lifeline for many patients.
59 
Let's personalize your content